- Home
- UMAC vs CYTH Comparison
UMAC vs CYTH Comparison
Compare UMAC & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- CYTH
- Stock Information
- Founded
- UMAC 2019
- CYTH 1990
- Country
- UMAC United States
- CYTH United States
- Employees
- UMAC N/A
- CYTH N/A
- Industry
- UMAC
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- UMAC
- CYTH Health Care
- Exchange
- UMAC Nasdaq
- CYTH Nasdaq
- Market Cap
- UMAC 20.4M
- CYTH 20.4M
- IPO Year
- UMAC 2024
- CYTH N/A
- Fundamental
- Price
- UMAC $3.22
- CYTH $0.71
- Analyst Decision
- UMAC Strong Buy
- CYTH Buy
- Analyst Count
- UMAC 1
- CYTH 3
- Target Price
- UMAC $4.00
- CYTH $0.95
- AVG Volume (30 Days)
- UMAC 126.4K
- CYTH 23.7K
- Earning Date
- UMAC 11-14-2024
- CYTH 11-14-2024
- Dividend Yield
- UMAC N/A
- CYTH N/A
- EPS Growth
- UMAC N/A
- CYTH N/A
- EPS
- UMAC N/A
- CYTH N/A
- Revenue
- UMAC $2,030,039.00
- CYTH $1,132,430.00
- Revenue This Year
- UMAC N/A
- CYTH N/A
- Revenue Next Year
- UMAC $66.18
- CYTH $24.49
- P/E Ratio
- UMAC N/A
- CYTH N/A
- Revenue Growth
- UMAC N/A
- CYTH 24.65
- 52 Week Low
- UMAC $0.98
- CYTH $0.59
- 52 Week High
- UMAC $5.54
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- UMAC 75.40
- CYTH 46.91
- Support Level
- UMAC $2.45
- CYTH $0.70
- Resistance Level
- UMAC $3.53
- CYTH $0.77
- Average True Range (ATR)
- UMAC 0.44
- CYTH 0.04
- MACD
- UMAC 0.15
- CYTH -0.00
- Stochastic Oscillator
- UMAC 85.24
- CYTH 28.38
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.